Gland Pharma to supply 252 million doses of Sputnik V vaccine to RDIF

Our Bureau Hyderabad | Updated on March 16, 2021

Production may start from 2021 Q3

Gland Pharma Ltd has agreed to supply up to 252 million doses of Sputnik V to Russian Direct Investment Fund, which has developed the Covid-19 vaccine with Gamaleya Research Institute of Epidemiology and Microbiology.

“This is the first of multiple partnerships being explored by Gland Pharma to leverage its manufacturing capacity and capabilities to support global supply of the Covid-19 vaccine,” the Hyderabad-based company said in a release on Tuesday.


“The agreement will see Gland Pharma utilising its Drug Substance and Drug Product facilities at its sites in Hyderabad,” the company said.

Production of the RDIF (Russian Direct Investment Fund) vaccine is expected to commence from the third quarter of 2021 for estimated delivery starting from the fourth quarter of 2021.

Terms of agreement

Under the terms of the agreement, Gland would first undertake technology transfer and then launch drug substance and product filling into vials under aseptic conditions.

Gland Pharma said that its expertise in manufacturing sterile injectable on a significant scale will help in establishing a stable supply line of Covid-19 vaccine. Dr Reddy’s, which is partnering RDIF, said on Monday that it has completed Phase-3 trials of Sputnik V vaccine and that it expects to announce the results early next month.

On the BSE, the Gland Pharma scrip closed at ₹2,718.65 on Tuesday, up 6.95 per cent over the previous close. RDIF had earlier tied up with Hyderabad-based Hetero for supply of over 100 million doses of Sputnik V.

Published on March 16, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor